MYE0 Stock Overview
A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
MaxCyte, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£3.08 |
52 Week High | UK£4.96 |
52 Week Low | UK£2.98 |
Beta | 1.16 |
11 Month Change | -7.23% |
3 Month Change | -13.97% |
1 Year Change | -19.37% |
33 Year Change | -60.00% |
5 Year Change | n/a |
Change since IPO | -58.10% |
Recent News & Updates
Recent updates
Shareholder Returns
MYE0 | DE Life Sciences | DE Market | |
---|---|---|---|
7D | -3.1% | 0.9% | -0.02% |
1Y | -19.4% | 2.7% | 8.2% |
Return vs Industry: MYE0 underperformed the German Life Sciences industry which returned 2% over the past year.
Return vs Market: MYE0 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
MYE0 volatility | |
---|---|
MYE0 Average Weekly Movement | 5.3% |
Life Sciences Industry Average Movement | 6.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MYE0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MYE0's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 143 | Maher Masoud | www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte, Inc. Fundamentals Summary
MYE0 fundamental statistics | |
---|---|
Market cap | €343.97m |
Earnings (TTM) | -€34.32m |
Revenue (TTM) | €43.79m |
7.9x
P/S Ratio-10.0x
P/E RatioIs MYE0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MYE0 income statement (TTM) | |
---|---|
Revenue | US$45.60m |
Cost of Revenue | US$6.39m |
Gross Profit | US$39.21m |
Other Expenses | US$74.94m |
Earnings | -US$35.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.34 |
Gross Margin | 85.98% |
Net Profit Margin | -78.37% |
Debt/Equity Ratio | 0% |
How did MYE0 perform over the long term?
See historical performance and comparison